Fidji Simo, one of OpenAI’s most prominent business and product leaders, is leaving her full-time role at the company and will continue as a part-time advisor. The decision follows a medical leave triggered by what Simo described as a severe exacerbation of a chronic illness she has lived with for seven years.

In a deeply personal post shared on X, Simo said the recovery process had proved “much longer and more complex” than she had anticipated. Rather than framing the shift as a departure from OpenAI’s mission, she positioned it as a necessary recalibration: a way to protect her health while retaining a connection to work she still believes in strongly.

It is a significant moment for OpenAI, but also an unusually candid one for a senior executive in an industry that tends to celebrate relentless intensity. Simo’s message is not simply a corporate leadership update. It is an account of someone whose career has been built on saying yes to big opportunities, now confronting the harder act of stepping back.

Simo said that doctors, colleagues, friends, and loved ones had encouraged her to slow down over the years. She recalled being offered a full year of medical leave while at Facebook and declining it immediately. In retrospect, she wrote, she wishes she had listened to advice to “play the long game.“

That reflection carries weight because Simo has spent much of her career moving through some of Silicon Valley’s most demanding jobs. Before OpenAI, she spent roughly a decade at Facebook, rising to lead the flagship Facebook app, then became CEO of Instacart in 2021. She joined OpenAI’s board in 2024 before being named CEO of Applications in 2025, reporting directly to Sam Altman.

The OpenAI appointment itself was designed to give the company more operational muscle as it expanded far beyond its roots as an AI research lab. Altman said Simo would help scale the company’s traditional business functions, while he remained responsible for OpenAI overall, with particular emphasis on research and compute.

For a company trying to turn an extraordinary wave of interest in ChatGPT and generative AI into a durable global business, Simo’s experience made clear sense. She had managed consumer products at Facebook’s enormous scale, then led Instacart through a period that demanded both product execution and commercial discipline. At OpenAI, her role reflected an increasingly familiar division of labor: researchers push the frontier, while senior operators make sure the products, partnerships, teams, and revenue engines can keep up.

Now that role will no longer be full-time.

Simo did not outline precisely what her advisory remit will include, or who will absorb her day-to-day responsibilities. But she made clear that the arrangement was supported by Altman, OpenAI president Greg Brockman, and the company’s board. She thanked them for giving her a way to keep contributing without sacrificing her chances of recovery.

Her decision also puts a human face on a reality that technology companies often struggle to acknowledge. Chronic illness is not a short interruption that can always be solved with a few weeks away from work. It can mean ongoing symptoms, treatment, appointments, insurance friction, uncertainty, and the less visible administrative load of being a patient. Simo said she had experienced that burden despite having what she called every possible advantage.

That experience appears to have sharpened, rather than weakened, her conviction about where AI can matter. Simo argued that some of the technology’s most meaningful opportunities lie in helping people manage the practical burdens of daily life, from health and finances to time and other routine pressures. She singled out curing disease as the most important thing AI could achieve, and said she intends to keep working toward that goal through OpenAI as well as Chronicle Bio and CODA Research.

There is an important distinction here. Simo is not making a generic claim that AI will solve healthcare overnight. Healthcare is full of hard constraints: clinical evidence, privacy, regulation, uneven access, and human judgment that cannot simply be automated away. But her comments point toward a more grounded ambition for AI – reducing the bureaucracy and confusion patients face, helping researchers move faster, and eventually supporting discoveries that take years through traditional methods.

The timing is notable. OpenAI has rapidly become one of the world’s most closely watched technology companies, with expectations that it will keep shipping products, compete aggressively for enterprise customers, and make the economics of advanced AI work at massive scale. Simo’s assignment was part of the company’s response to that pressure. TIME described her role as an effort to help guide OpenAI toward profitability while it navigated a costly growth phase.

Yet the core of Simo’s announcement is not about OpenAI’s corporate structure. It is about rejecting the idea that professional endurance is the same thing as long-term impact. “Grit and endurance are not the only skills required to have impact over decades,” she wrote, arguing that taking care of oneself now can make future contribution possible.

That may be the line people remember most. In a field where ambitious executives are routinely praised for working through exhaustion and treating availability as a measure of commitment, Simo is offering a more complicated model of leadership. She is still connected to the work. She still believes technology can help solve hard human problems. But she is no longer treating her own health as something to be deferred indefinitely.

OpenAI will have to manage the operational implications of losing a full-time executive at a consequential point in its evolution. For Simo, though, the change is more personal and more immediate: recovery comes first, while the advisory role leaves the door open for her to contribute on terms that are sustainable.